II. Indications

  1. Acute Myelogenous Leukemia (AML)
    1. Gemtuzumab ozogamacin

III. Mechanism

  1. CD33
    1. CD33 is a small Protein on the surface of myeloid cells and Monocyte-Macrophage precursors
    2. CD33 interacts with SHP-1 and SHP-2 Protein kinases for intracellular signaling
  2. CD33 Monoclonal Antibody
    1. Conjugate antibodies that deliver cytotoxic drugs to CD33 positive cancer cells

IV. Medications

  1. Gemtuzumab ozogamacin (Mylotarg)
    1. Conjugated Monoclonal Antibody that delivers the cytotoxic drug calicheamicin to cancer cells
    2. Used in Acute Myelogenous Leukemia (AML)

V. Dosing

  1. See other references for disease specific dosing protocols

VI. Adverse Effects

  1. Hepatotoxicity (FDA black box warning)
    1. Includes hepatic veno-occlusive disease (sinusoidal obstruction)
    2. Increased transaminases, GGT, and Serum Bilirubin
  2. Infusion Reactions (including Anaphylaxis)
  3. Severe Hemorrhage
  4. Other common adverse effects
    1. Gastrointestinal (Nausea, Vomiting, Constipation, decreased appetite)
    2. Headache
    3. Rash
    4. Mucositis

VII. Safety

  1. Avoid in Lactation
  2. Avoid in pregnancy (all trimesters, Unknown Pregnancy category)
    1. Use reliable Contraception
  3. Monitoring
    1. Liver Function Tests
    2. Complete Blood Count with Platelet Count

Images: Related links to external sites (from Bing)

Related Studies